Liver International

🔥 🆙 to publish this work with @HD3vedi and team regarding the importance of #exercise across all types and stages of steatotic liver disease! Check it out here: onlinelibrary.wiley.com/doi/10.1111/li…

You can continue #Anticoagulation when you perform #endoscopicbandligation #ELB for #varices When Undergoing Endoscopic Variceal Ligation: A Systematic Review and Meta‐Analysis @LiverInt 🔗onlinelibrary.wiley.com/doi/10.1111/li…

Anticoagulation did 🚫increase the risk of bleeding With/without anticoagulation during EVL, we found a similar risk of: 1) Overall bleeding 2) Severe bleeding 3) Post-banding ulcer bleeding #Livertwitter 👉doi.org/10.1111/liv.16……

Very excited to have the final paper from my #PhD published #OpenAccess in @LiverInt While #HCV DAA treatment is highly effective, it is important to understand why a small minority are not cured. We aimed to do this with data from 🇦🇺🇨🇦🇫🇷🇳🇱🇪🇸🇨🇭 onlinelibrary.wiley.com/doi/10.1111/li…

In this @LiverInt study, researchers from #Japan shed light on how #MICOS defects impair #mitochondrial function in #MitochondrialDNAdepletionSyndrome, opening new avenues for genetic testing and therapies. Learn more: doi.org/10.1111/liv.16…

2/2 💡 The clinical impact? Using genetics to interpret LBTs may reduce false positives/negatives, optimize resources, and improve diagnostics further validation in diverse populations is needed! 🌍🩺 #livertwitter

1/2 ⬆️ liver tests may not always indicate a higher risk of serious liver disease Genetic variants influencing common liver test results (like GGT & bilirubin) don't always correlate with higher cirrhosis risk 🤔 🔓bit.ly/3VgbxO4 #livertwitter

The number and type of metabolic syndrome traits have important impacts on the risk of CKD and incident ESRD in people with MASLD. @EScorletti, @Alessan95336031, @LiverInt Read our recent work here: onlinelibrary.wiley.com/doi/10.1111/li…

🚨 Out now in @LiverInt: New scenarios in LT for HCC 👥 Led by a great international team in the field. @Alexfornergon @goncrespo1 @A_DAlessioMD @DJPinato @ColmeneroJordi @liverunitclinic @hospitalclinic @idibaps @BCLC_group @CHBPaulBrousse @HUReinaSofia onlinelibrary.wiley.com/doi/10.1111/li…

G-CSF is not inferior to corticosteroids in improving 90-day overall survival and 6-months transplant free survival in patients with severe alcohol-associated hepatitis. Singh et Al @LiverInt onlinelibrary.wiley.com/doi/full/10.11… #livertwitter #GITwitter

Our latest review on the impact of #PNPLA3 variants on clinical outcomes in #MASLD is out in @LiverInt open access @salvatore_petta @lucavalenti75 @stefano_romeo76 onlinelibrary.wiley.com/doi/full/10.11…

🚨 New Research Alert! 🚨 Latest paper in @LiverInt by the @OhioStateSurg TEAM explores the impact of #GLP1RA on adverse liver outcomes among patients with #Alcohol associated #liver disease and type 2 #diabetes Link 👉 doi.org/10.1111/liv.16… 💡Key finding GLP-1RA = ⬇️ incidence of adverse liver outcome particularly #hepatic #decompensation @timpawlik #MedTwitter @ProjectImg

🔴Our work about the burden of hepatitis D in the context of reflex testing has received over 500 views since publication! 📃Read it here onlinelibrary.wiley.com/doi/10.1111/li… #ViewsMilestone @Mariabutif @AEEHLiver @LiverInt

What a news from @LiverInt! 🥳 Our review on CARVEDILOL IN PORTAL HYPERTENSION has received over 20,000 views since publication! 🥰 @ReibergerThomas @VincenzoLaMura @GiovanniVitale 🔽 onlinelibrary.wiley.com/doi/10.1111/li… #ViewsMilestone

Necesidades no cubiertas en pacientes con hepatitis autoinmune (y son unas cuantas): 👉 Solo el 62% de los pacientes logran respuesta completa tras 1 año de tto ⚠️ Apenas el 27% lo consigue sin esteroides 🔄 30% de los pacientes cambian de tratamiento por intolerancia o no respuesta 📉 Heterogeneidad extrema en los tratamientos entre centros ❌ Necesitamos más alternativas terapéuticas efectivas y seguras 🔓 doi.org/10.1111/liv.16… en @LiverInt Detalle relevante: tampoco debería sorprendernos, el tto estándar tiene 50 años! #livertwitter #HAI

🚨#livertwitter #Hepatitis #HCV #Elimination 🇦🇹 Austrian #HCV Elimination Project supported @GileadSciences 5695 #HCV patients screened 397 started on #Antivirals #DAA 326 #HCV patients cured #SVR ✅ #HepC Cure 😇 Survival Benefit 📕@LiverInt 🔗t.ly/UFbQ6

New insights into liver fibrosis in @LiverInt! SHG/TPEF microscopy with #AI offers precise assessment of #fibrosis in MASH F3 patients, revealing changes even when standard scoring shows 'no change.' #livertwitter @DavidKleiner12 bit.ly/3Tyu8nG

“The Liver would be better” The story behind Neruda’s ode to the liver by @MarcoArreseMD in @LiverInt onlinelibrary.wiley.com/doi/full/10.11…

Just recently published at @LiverInt , our work on waitlist outcomes and post-transplant outcomes in MASLD/AIH. We found better waitlist outcomes on MASLD/AIH compared to MASLD and AIH. No differences on post-LT outcomes.@BonderAlan @HD3vedi @AnaMarencoMD onlinelibrary.wiley.com/share/author/P…

2/2 ‼️ Despite its efficacy, 31% of patients experienced relapses, successfully managed with additional Rituximab cycles While promising, prospective studies are needed to validate these findings in advanced #AIH #livertwitter

1/2 A multicenter 🇪🇸 study shows that #Rituximab is a safe & effective option for patients with refractory autoimmune hepatitis It achieved complete biochemical response in 89% of cases, ⬇️ need for immunosuppressants & corticosteroids 🔓 bit.ly/4ehFh4u #Livertwitter